Submit CT Protocol, Toxicity Report: CDSCO panel Tells Glenmark on respiratory drug combination Dr. Divya Colin7 Oct 2022 6:00 PM ISTNew Delhi: Directing to conduct Phase III clinical trail and inhalation toxicity study of respiratory fixed dose combination drug Glycopyrronium...
Allergic Rhinitis in Children: Practitioners Update and Consideration for Use of Intranasal Fluticasone Based Therapies Dr. Kamal Kant Kohli23 Aug 2022 12:45 PM ISTAllergic rhinitis (AR), an inflammatory disease caused by an IgE-mediated immune response to inhaled allergens, is a frequently occurring childhood...
Management of Allergic Rhinitis during COVID-19 Pandemic Dr. Kamal Kant Kohli27 Jun 2022 12:00 PM ISTThe COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) has challenged the healthcare systems and altered the...
Glenmark Gets CDSCO panel nod to market asthma, COPD drug Dr. Divya Colin14 Jun 2022 6:30 PM ISTNew Delhi: Granting the waiver of bioequivalence study, the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization...
Novel therapies in managing Allergic rhinitis: How far have we come? Dr. Kamal Kant Kohli8 Jun 2022 12:45 PM ISTAllergic rhinitis(AR) is a common respiratory condition affecting 40 % of the worldwide population. Due to its shared pathophysiology with...
Air pollution and allergic rhinitis: Understanding the invisible, yet the inevitable connection Dr. Kamal Kant Kohli19 May 2022 12:54 PM ISTThe spiking frequency of allergic respiratory illness over the last several decades, and the increasing rate of air pollution owing to urbanization,...
Review: Patient preferences for Intranasal Corticosteroids on account of Sensory Attributes Dr. Kamal Kant Kohli11 April 2022 9:00 AM ISTIntranasal corticosteroids are the pillar treatment for allergic rhinitis, a broad disease that affects over 500 million people around the world...
Review: Intranasal corticosteroids in Allergic rhinitis Dr. Kamal Kant Kohli28 Feb 2022 11:54 AM ISTAllergic Rhinitis is one of the most common persistent conditions for which clinical intervention is sought and is a significant cause of widespread...
Cadila Healthcare gets CDSCO panel okay for Fluticasone Furoate, Oxymetazoline HCL nasal spray Medical Dialogues Team19 July 2021 1:00 PM ISTNew Delhi: In a major rejoice for pharma major Cadila Healthcare, the Subject Expert Committee (SEC) of the Central Drugs Standard Control...
Triple drug inhaler may effectively reduce COPD exacerbations Dr. K B Aarthi19 March 2020 6:15 PM ISTDaily use of triple-drug FF/UMEC/VI inhaler led to significant reductions in moderate/severe COPD exacerbations, hospitalizations and death.
